34 results about "Delayed hypersensitivity" patented technology

The invention discloses external traditional Chinese medicine composition with effects of relieving allergy and resisting irritation. The external traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 1-20 parts of campsis grandiflora, 1-10 parts of muskmelon root, 1-10 parts of root of straight ladybell, 1-15 parts of cactuses, 1-10 parts of radix sophorae flavescentis, 1-10 parts of radix ophiopogonis and 1-10 parts of hydrangea aspera don. Experiments prove that the composition has an antagonistic effect on irritation of surfactants and preservatives in cosmetics, has effective effects of inhibiting allergy and relieving itching, and has effects of inhibiting type I hypersensitivity (immediate hypersensitivity) by reducing the content of IL-6 (interleukin-6) and inhibiting type IV hypersensitivity (delayed hypersensitivity) by reducing the content of IL-8. The composition further has effects of whitening and moisturizing skin and achieves the effect of a skin barrier. The raw materials are easily available, a preparation method is simple, convenient, environment-friendly and safe, and the composition is easily accepted by people suffering from allergies, thereby having very good application and market prospects.

Procedure for obtaining Olea Europea extracts from Olea Europea leaves dried at less than 35° C. with alkanols at a low temperature and extract purificationNew pharmacological applications of Olea Europea extracts as an agent reinforcing cellular immunity and delayed hypersensitivity in healthy humans, activating and proliferating T-lymphocytes, Natural Killer cells, monocytes and granulocytes, and pro-inflammatory cytokins.

The invention discloses a traditional Chinese medicinal health food having fatigue preventing and immunity enhancing effects. The health food is prepared from, by weight, 50-150 parts of hairy antler,150-400 parts of epimedium herb, 250-450 parts of Fructus Tribuli, 150-400 parts of ginseng, 150-400 parts of Radix Puerariae, 150-400 parts of mulberry and 150-400 parts of Polygonatum sibiricum. The invention also discloses a preparation method of the health food. The health food can prolong the weight-loading swimming of mice, increase the number of antibody-producing cells in the mice, increase the half hemolysis value of the serum of the mice and improve the delayed hypersensitivity of the mice, so the health food has the fatigue preventing and immunity enhancing functions.

The invention provides an application of Incarvillea delavay alkali in preparing a drug for resisting autoimmune diseases and graft rejection diseases. Experiments show that the Incarvillea delavay alkali can inhibit human dendritic cell proliferation in vitro, prevent the human dendritic cells from accelerating the proliferation reaction of allogeneic T cells, and strengthen the capability of the human dendritic cell on secreting interleukin. Meanwhile, in the model of the experimental autoimmune disease cerebrospinal meningitis, the Incarvillea delavay alkali is applied in vivo so as to lower average clinical scores of mice and inhibit the spinal cord infiltration degree of mononuclear cells. In a heart transplantation experiment, the Incarvillea delavay alkali is applied in vivo to prolong the survival time of a transplanted heart. In a delayed hypersensitivity reaction model, the Incarvillea delavay alkali is applied in vivo to lower the auricle swelling degree of the mice. In-vivo and in-vitro results show that the Incarvillea delavay alkali has certain action on resisting autoimmune diseases and graft rejection diseases. The drug provided by the invention is a preparation composed of the Incarvillea delavay alkali which serves as an active ingredient, and a medicinal carrier. The drug can be in an oral agent form, an injection form, a suppository form or an external dosage form and the like.

The invention discloses a product based on a nontuberculous-mycobacterium purified protein derivative and a recombinant mycobacterium tuberculosis fusion protein, application and a use method and belongs to the technical field of biological proteins. Tuberculosis and a NTM disease can be rapidly and accurately identified through combined use of the nontuberculous mycobacterium purified protein derivative and the recombinant mycobacterium tuberculosis fusion protein (EEC), and when delayed hypersensitivity reactions of the nontuberculous mycobacterium purified protein derivative and the recombinant mycobacterium tuberculosis fusion protein are all positive, the tuberculosis is determined; and when the delayed hypersensitivity reaction of the nontuberculous-mycobacterium purified protein derivative is positive and the delayed hypersensitivity reaction of the recombinant mycobacterium tuberculosis fusion protein is negative, the NTM disease is determined. The invention provides the product based on the nontuberculous-mycobacterium purified protein derivative and the recombinant mycobacterium tuberculosis fusion protein and the application of the product, so that the tuberculosis and the NTM disease are quickly and accurately identified, and a reliable basis is provided for the aspects of early diagnosis, treatment and the like of patients.

The invention relates to a cyclic peptide which is provided with a residue fragment of -Val-Sta-Leu- and is used as immunosuppressive agents, and the synthesis process of the cyclic peptide (Ile-Ile-Pro-Pro-Tyr-Val-Sta-Leu) consists of 1) removing amino-protecting groups, 2) transpeptidase reaction, 3) the cutting of a peptide chain, 4) cyclization of the peptide chain. The cyclic peptide compounds which are provided with the residue fragment of Val-Sta-Leu- and used as immunosuppressive agents and have a high yield and a high purity can be obtained, and the immunosuppressive activity of the cyclic peptide compounds is higher. Through the experiments of the retarding effect of A3HS1 towards the delayed hypersensitivity of mice, the influence of phagocytic function of macrophages, and the retarding effect of the proliferation of lymphocytes, the A3HS1 shows a stronger immunosuppressive effect than HS-1, which reaches or surpasses the immunosuppressive of the positive contrast (cyclosporine).

An application of fumigaclavine C in treating Crohn's disease, ulcerative colitis, and T cell-related autoimmune diseases, such as delayed hypersensitivity, multiple sclerosis, insulin-dependent diabetes, etc, is disclosed.

The invention relates to the application of ginseng alkynol for preparing medicine treating delayed hypersensitivity diseases, in particular to the application of the ginseng alkynol for preparing the medicine treating contact dermatitis, the application of the ginseng alkynol for preparing the medicine treating hypersensitivity pneumonia, the application of the ginseng alkynol for preparing the medicine treating homograft rejection, and the application of the ginseng alkynol for preparing the medicine treating granulomatosis caused by pathogene in cells. The ginseng alkynol is used as main active ingredient used for treating the delayed hypersensitivity diseases, can obviously inhibit the diseases mediated by delayed hypersensitivity, has no obvious inhibition to immune organs and other cells, and is hopeful to be higher effective and lower toxic medicine used for treating the delayed hypersensitivity diseases.

The invention relates to cyclic peptide used as immunosuppressant and carried with -Pro-Sta-Tyr- residue fragment as well as ring (Ile-Ile-Pro-Sta-Tyr-Val-Pro-Leu). The synthesis process of the invention is as follows: (1) amino protecting group is removed; (2) synthesized peptide is completed; (3) peptide chain cutting is carried out; (4) peptide chain cyclization is completed. Therefore, a cyclic peptide compound, which has high yield, high purity and -Pro-Sta-Tyr- residue fragment and can be used as immunosuppressant, can be obtained; moreover, the compound has higher immunosuppression activity. The experiments on the inhibition of A2HS1 on mouse delayed hypersensitivity, the influence on the phagocytic capability of macrophage and the inhibition on lymphopoiesis show that the A2HS1 represents stronger natural immunosuppression than HS-1 and reaches or exceeds positive contrast (cyclosporin) immunosuppression.

A new immunosuppressive agent as glycyrol has significant immunosuppressive activity, thus is useful as an immunosuppressive agent to treat relative diseases, wherein the glycyrol is a coumestrol compound extracted from glycyrrhiza, which is a small molecular compound with novel chemical structure. Tests prove that the glycyrol can inhibit the increment of T lymphocyte induced by canavaline A and inhibit one-way mixed lymphocyte reaction (MLR), release the inflammatory symptom of delayed hypersensitivity and inhibit the homologous allogenic organ transplantation rejection. The glycyrol is a high-effective low-toxicity immunosuppressive agent, with small molecular weight and simple structure, which is easy to be modified and to prepare different drug agents, therefore, the compound is a new generation immunosuppressive agent.